Cardiometabolic News and Research RSS Feed - Cardiometabolic News and Research

Liraglutide drug combined with diet and exercise promotes weight loss in diabetic patients

Liraglutide drug combined with diet and exercise promotes weight loss in diabetic patients

Among overweight and obese patients with type 2 diabetes, daily injection of the diabetes drug liraglutide with a modified insulin pen device, in addition to diet and exercise, resulted in greater weight loss over 56 weeks compared with placebo, according to a study in the August 18 issue of JAMA. [More]
Alere supports DTHF’s Tutu Teen Truck project to expand reach of infectious services for youth

Alere supports DTHF’s Tutu Teen Truck project to expand reach of infectious services for youth

Alere Inc. (NYSE: ALR), a global leader in rapid diagnostics, today announced a grant of 2.5 million South African Rand to support the work of the Desmond Tutu HIV Foundation (DTHF), a Cape Town-based organization under the patronage of Archbishop Emeritus Desmond Tutu. [More]
Leading researchers, policymakers and health professionals to discuss on obesity, weight loss at ObesityWeek 2015

Leading researchers, policymakers and health professionals to discuss on obesity, weight loss at ObesityWeek 2015

More than 1,500 research abstracts will be presented on new and emerging obesity treatments, the science of weight loss, new prevention strategies, metabolic surgery, digital health technology and public policy, when thousands of leading researchers, policymakers and health professionals gather for ObesityWeek 2015 at the Los Angeles Convention Center in California from November 2 to 7, 2015. [More]
Resverlogix announces formation of international Clinical Steering Committee for RVX-208 "apabetalone" Phase 3 trial

Resverlogix announces formation of international Clinical Steering Committee for RVX-208 "apabetalone" Phase 3 trial

Resverlogix Corp. is pleased to announce the formation of an international Clinical Steering Committee for the RVX-208 "apabetalone" Phase 3 clinical trial BETonMACE assessing major adverse cardiac events (MACE) in high-risk vascular patients with diabetes mellitus and a recent Acute Coronary Syndrome event. BETonMACE is expected to start in the fall of 2015. [More]
NEJM publishes positive clinical results from Phase 2 clinical study of volanesorsen

NEJM publishes positive clinical results from Phase 2 clinical study of volanesorsen

Isis Pharmaceuticals, Inc., the leader in RNA-targeted therapeutics, and Akcea Therapeutics, its wholly owned subsidiary, announced today that The New England Journal of Medicine (NEJM) has published positive clinical results from a Phase 2 clinical study evaluating volanesorsen (formerly ISIS-APOCIII Rx) in patients with very high to severely high triglycerides. [More]

Alere announces two transactions to further strengthen its core business strategy

Alere Inc., a global leader in rapid diagnostics, announced today two transactions that further strengthen the Company's focus on its core business strategy. [More]
FDA grants CLIA waiver for Alere i Strep A test

FDA grants CLIA waiver for Alere i Strep A test

Alere Inc., a global leader in rapid diagnostic tests, today announced that the U.S. Food and Drug Administration has granted CLIA waiver for the Alere i Strep A test. The test, which was cleared for marketing by the FDA in April 2015, is the first molecular platform that detects Group A Streptococcus (GAS) bacteria in 8 minutes or less. [More]
Virginia Tech researchers develop new scoring method for assessing overall beverage intake quality

Virginia Tech researchers develop new scoring method for assessing overall beverage intake quality

Researchers at Virginia Tech have developed a new scoring method for assessing beverage intake, the Healthy Beverage Index (HBI). In a report published in the Journal of the Academy of Nutrition and Dietetics they describe how this tool can be used to more accurately evaluate dietary consumption of all types of fluids. [More]
Akcea Therapeutics obtains FDA Orphan Drug Designation for volanesorsen

Akcea Therapeutics obtains FDA Orphan Drug Designation for volanesorsen

Akcea Therapeutics, a wholly-owned subsidiary of Isis Pharmaceuticals, Inc., announced today that the U.S. Food and Drug Administration has granted Orphan Drug Designation to volanesorsen (ISIS-APOCIIIRx) for the treatment of patients with Familial Chylomicronemia Syndrome (FCS). [More]
Researchers analyze cardiometabolic benefits of exercise

Researchers analyze cardiometabolic benefits of exercise

Everyone knows that exercise generally helps the cardiovascular system, but much remains unknown about how the benefits arise, and what to expect in different people who exercise to improve their health. To gain a more precise understanding of how exercise improves health and whom it helps most, researchers analyzed the results of 160 randomized clinical trials with nearly 7,500 participants. [More]
Drinking low-calorie cranberry juice may help lower risk of heart disease, diabetes and stroke

Drinking low-calorie cranberry juice may help lower risk of heart disease, diabetes and stroke

A new study reveals that drinking low-calorie cranberry juice cocktail may help lower the risk of chronic diseases that rank among the leading causes of death worldwide, including heart disease, diabetes and stroke. The finding is welcome news considering the World Health Organization estimates the trio of diseases annually claim 15.6 million lives around the globe. [More]

Alere announces cash dividend of $3.00 per share on its Series B Convertible Perpetual Preferred Stock

Alere Inc., a global leader in rapid diagnostics, today has declared a cash dividend of $3.00 per share on its Series B Convertible Perpetual Preferred Stock (NYSE: ALR.PR.B). [More]
MHICN expands clinical research program in collaboration with Erasmus Medical Center and ErasmusAGE

MHICN expands clinical research program in collaboration with Erasmus Medical Center and ErasmusAGE

Metagenics Healthcare Institute for Clinical Nutrition announced today an expanded clinical research program in collaboration with Erasmus Medical Center and ErasmusAGE, from Rotterdam, the Netherlands – a leading global healthcare center in epidemiology and health outcomes research. [More]
Boehringer Ingelheim, University of Michigan partner to discover new medicines for diabetic nephropathy

Boehringer Ingelheim, University of Michigan partner to discover new medicines for diabetic nephropathy

Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy. [More]
Accelerated brain aging related to cognitive complications observed in people with type 1 diabetes

Accelerated brain aging related to cognitive complications observed in people with type 1 diabetes

The brains of people with type 1 diabetes show signs of accelerated aging that correlate with slower information processing, according to research led by the University of Pittsburgh Graduate School of Public Health. [More]
Study: Cardiorespiratory fitness associated with reduced metabolic syndrome risk among smokers

Study: Cardiorespiratory fitness associated with reduced metabolic syndrome risk among smokers

Cardiorespiratory fitness is associated with reduced metabolic syndrome risk among smokers, according to researchers from The University of Texas Health Science Center at Houston (UTHealth) School of Public Health. [More]
Alere i Strep A test receives marketing clearance from FDA

Alere i Strep A test receives marketing clearance from FDA

Alere Inc., a global leader in rapid diagnostic tests, today announced that its Alere i Strep A test has received marketing clearance from the U.S. Food and Drug Administration. Alere i Strep A is the first molecular test that detects Group A Streptococcus (GAS) bacteria in throat swab specimens in 8 minutes or less. [More]
CVD risk assessment still important in severely obese adolescents

CVD risk assessment still important in severely obese adolescents

Researchers report a dose–response relationship between body mass index and cardiovascular risk even in severely obese adolescents, making its assessment important to limit further disease progression. [More]
Study finds clustered cardiometabolic risk factors in children

Study finds clustered cardiometabolic risk factors in children

Lifestyle-related cardiometabolic risk factors cluster already in children in the same way as in adults, according to research from the University of Eastern Finland. A cardiometabolic risk score was used to evaluate cardiometabolic risk in different age groups. [More]
Vitamin D plays major role in preventing diabetes and atherosclerosis

Vitamin D plays major role in preventing diabetes and atherosclerosis

In recent years, a deficiency of vitamin D has been linked to type 2 diabetes and heart disease, two illnesses that commonly occur together and are the most common cause of illness and death in Western countries. Both disorders are rooted in chronic inflammation, which leads to insulin resistance and the buildup of artery-clogging plaque. [More]
Advertisement
Advertisement